About 81 adults with CCH (mean age, 49 years; 74% men) who failed to respond to standard prophylactic therapies were randomly assigned to receive either subcutaneous erenumab (280 mg at baseline ...

A study confirms these substances are effective for both prophylactic and acute treatment of cluster headache and migraines. Get our list of 10 overlooked stocks—including one paying a 9% ...